Trials / Completed
CompletedNCT02583516
Clinical Trial to Evaluate the Efficacy of Vemurafenib in Combination With Cobimetinib (Continuous and Intermittent) in BRAFV600-mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
A Randomized Phase II Study of Vemurafenib Plus Cobimetinib Continuous Versus Intermittent, in Previously Untreated BRAFV600- Mutation Positive Patients With Unresectable Locally Advanced or Metastatic Melanoma
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Grupo Español Multidisciplinar de Melanoma · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the efficacy and safety of two different schedules of administration of vemurafenib in combination with cobimetinib (continuous and intermittent) in previously untreated BRAFV600- mutation positive patients with unresectable locally advanced or metastatic melanoma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | vemurafenib and cobimetinib | Comparison between different treatment regimens |
Timeline
- Start date
- 2015-06-30
- Primary completion
- 2019-09-30
- Completion
- 2019-09-30
- First posted
- 2015-10-22
- Last updated
- 2020-02-17
Locations
18 sites across 1 country: Spain
Source: ClinicalTrials.gov record NCT02583516. Inclusion in this directory is not an endorsement.